Analysis on prognostic influencing factors of immunotherapy for advanced non-small cell lung cancer
10.3969/j.issn.1671-8348.2025.02.024
- VernacularTitle:晚期非小细胞肺癌免疫治疗的预后影响因素分析
- Author:
Kai DENG
1
;
Chenghui LI
Author Information
1. 安徽医科大学安庆医学中心,安徽安庆 246000;安徽医科大学附属第五临床医学院,安徽安庆 246000
- Keywords:
advanced lung cancer;
non-small cell lung cancer;
immunotherapy;
palliative radiotherapy;
prognosis
- From:
Chongqing Medicine
2025;54(2):430-435
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the prognosis related influencing factors of immunotherapy in the pa-tients with advanced non-small cell lung cancer(NSCLC)to provide reference for clinical treatment and prog-nosis evaluation of the patients.Methods The clinical data of 132 patients with advanced NSCLC receiving the immunotherapy admitted and treated in the Anqing Medical Center of Anhui Medical University from Oc-tober 2019 to June 2022 were retrospectively analyzed.The overall survival(OS)and progression-free survival(PFS)of the patients were statistically analyzed.The Cox univariate and multivariate models were used to an-alyze the prognosis related influencing factors.Results The median OS time in 132 cases was 20.10 months and the median PFS time was 14.95 months.The results of multi-factor analysis showed that the ECOG score,number of treatment lines and receiving palliative radiotherapy were the independent influencing factors of OS time in the patients with advanced NSCLC(P<0.05).Hemoglobin,C-reactive protein(CRP),ECOG score and number of treatment lines were the independent risk factors of PFS time in the patients with ad-vanced NSCLC(P<0.05).Conclusion The patients with hemoglobin≥110 g/L,CRP<6 mg/L,ECOG score 0-1 point,first line immunotherapy,receiving palliative radiotherapy could obtain the benefit from immunotherapy.
